Latest revenue
—
as of 2025-12-31
Latest net income
$-77.9M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ACRV is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $60.8M
- Enterprise value
- $26.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.64×
- Dividend yield
- 0.0%
- 52-wk high
- $3.56
- 52-wk low
- $1.15
- Beta
- —
- Shares out
- 42.8M
5-year trend
What this company does
Acrivon Therapeutics is a clinical-stage biotech developing cancer drugs matched to patients using its proprietary proteomics platform, AP3, which measures drug effects on tumor proteins rather than relying on genetic mutations. The company generates no product revenue and funds operations through capital raises while advancing its pipeline, led by ACR-368 (prexasertib), licensed from Eli Lilly. The pivotal development is ACR-368's Phase 2b trial in endometrial cancer, where interim data showed a 52% confirmed response rate in serous EC patients, prompting expansion into biomarker-unselected cohorts.
Generated from ACRV's filing dated 2026-03-19
Key risks
- Pipeline concentration: lead asset ACR-368 is in-licensed from Lilly and was previously deprioritized; success hinges on unapproved OncoSignature companion diagnostic.
- Small interim data set: 39% confirmed ORR in EC Arm 1 may not replicate; new 'serous all-comer' arms 3/4 lack biomarker stratification, raising readout risk.
- Clinical-stage with no approved products; OncoSignature CDx unapproved and ACR-6840 IND not planned until Q4 2026, implying continued cash burn and dilution risk.
Generated from ACRV's filing dated 2026-03-19
Profitability
Return on equity
-44.1%
33.7%Return on assets
-60.1%
46.6%Leverage
Debt / equity
-0.27×
142.8%Debt / assets
-36.3%
194.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-19.0M | +3.2% | — |
Q4 2025 2025-12-31 | — | — | $-19.0M | +16.8% | — |
Q3 2025 2025-09-30 | — | — | $-18.2M | +18.7% | — |
Q2 2025 2025-06-30 | — | — | $-21.0M | -11.7% | — |
Q1 2025 2025-03-31 | — | — | $-19.7M | -19.4% | — |
Q4 2024 2024-12-31 | — | — | $-22.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-22.4M | -55.1% | — |
Q2 2024 2024-06-30 | — | — | $-18.8M | -35.1% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ACRV — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$114.3K
Insider selling
$0
Net activity
+$114.3K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ACRV
Institutional value
$4.9M
Total shares held
4.5M
Distinct holders
22
-26 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Sands Capital Ventures, LLC | 2.1M | $3.0M | +0 (+0.0%) | No change |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 722.0K | $1.0M | — | New |
| 3 | JANE STREET GROUP, LLC | 239.7K | $333.2K | -102.4K (-29.9%) | Trimmed |
| 4 | BlackRock, Inc. | 208.9K | $290.4K | +3.8K (+1.9%) | Added |
| 5 | VANGUARD FIDUCIARY TRUST CO | 107.5K | $149.5K | — | New |
| 6 | UBS Group AG | 34.6K | $48.1K | -313.9K (-90.1%) | Trimmed |
| 7 | DIMENSIONAL FUND ADVISORS LP | 18.4K | $25.4K | +0 (+0.0%) | No change |
| 8 | AAF Wealth Management, LLC | 10.7K | $14.8K | +0 (+0.0%) | No change |
| 9 | Marex Group plc | 10.0K | $13.9K | +0 (+0.0%) | No change |
| 10 | FEDERATED HERMES, INC. | 7.9K | $11.0K | +2.3K (+41.2%) | Added |
| 11 | Vanguard Global Advisers, LLC | 4.5K | $6.2K | — | New |
| 12 | WELLS FARGO & COMPANY/MN | 3.0K | $4.2K | — | New |
| 13 | ACADIAN ASSET MANAGEMENT LLC | 846.0K | $1.2K | +264.8K (+45.6%) | Added |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 634 | $881 | +0 (+0.0%) | No change |
| 15 | JPMORGAN CHASE & CO | 638 | $823 | -16.2K (-96.2%) | Trimmed |
| 16 | NISA INVESTMENT ADVISORS, LLC | 584 | $812 | +0 (+0.0%) | No change |
| 17 | Redwood Park Advisors LLC | 500 | $695 | +0 (+0.0%) | No change |
| 18 | Russell Investments Group, Ltd. | 481 | $669 | +0 (+0.0%) | No change |
| 19 | Steward Partners Investment Advisory, LLC | 326 | $453 | — | New |
| 20 | GSA CAPITAL PARTNERS LLP | 186.7K | $260 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Arm 1 endometrial ORR was 39% but serous all-comer pooled hit 52%—does this undermine OncoSignature's value as a companion diagnostic?
- 2
With ACR-6840 IND slipping to Q4 2026 and two ongoing Phase 2b arms, what's current cash runway and when do you raise?
- 3
Lilly dosed prexasertib in 400+ patients without advancing it—what specifically did their internal data miss that justifies your registrational bet?
Refreshed when ACRV files a new report · last from 2026-03-19
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.